07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Fresenius, Teva, Eli Lilly cancer news

The U.S. District Court for the Southern District of Indiana found that eight claims of Lilly's U.S. Patent No. 7,772,209 regarding the co-administration of folic acid and vitamin B12 with cancer drug Alimta pemetrexed is...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Lipodox doxorubicin regulatory update

FDA said it will allow the temporary importation and distribution of cancer drug Lipodox doxorubicin from Sun to address the shortage in the U.S. of Doxil doxorubicin from Johnson & Johnson. Doxil has been in...
01:38 , Feb 22, 2012 |  BC Extra  |  Company News

FDA importing foreign cancer drug to address Doxil shortage

FDA said it will allow the temporary importation and distribution of cancer drug Lipodox doxorubicin from Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) to address the shortage in the U.S. of Doxil doxorubicin from Johnson &...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Company News

Fresenius SE, Medicines Co. cardiovascular news

The Medicines Co. and Fresenius' APP Pharmaceuticals Inc. generics unit resolved patent litigation related to Angiomax bivalirudin from Medicines Co. Under the settlement, APP admits that U.S. Patent Nos. 7,582,727 and 7,598,343 owned by Medicines...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Company News

Fresenius SE deal

Fresenius said in a 10-K filing that APP Pharmaceuticals Inc. did not reach the required threshold in consolidated adjusted EBITDA and will therefore not be eligible for a contingent value rights (CVRs) payment of $970...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Company News

Medicines Co. cardiovascular news

The U.S. Solicitor General declined to appeal a district court decision requiring the U.S. Patent and Trademark Office (PTO) to consider a patent term extension application from The Medicines Co. for anticoagulant Angiomax bivalirudin as...
07:00 , Sep 13, 2010 |  BioCentury  |  Finance

Regulatory milestones

Forest Laboratories Inc. (NYSE:FRX) gained $0.18 to $29.74 last week after FDA's Anti-Infective Drugs Advisory Committee voted unanimously that ceftaroline was a safe and effective treatment for community-acquired bacterial pneumonia (CABP) and complicated skin and...
23:10 , Sep 10, 2010 |  BC Extra  |  Company News

Court denies APP motion in Angiomax suit

The U.S. District Court for the Eastern District of Virginia denied a motion from APP Pharmaceuticals Inc. to intervene in a case regarding an application from The Medicines Co. (NASDAQ:MDCO) to extend the patent term...
01:09 , Sep 10, 2010 |  BC Extra  |  Company News

Solicitor General declines to appeal Angiomax decision

The Medicines Co. (NASDAQ:MDCO) gained $1.44 (12%) to $13.17 on Thursday after the U.S. Solicitor General declined to appeal a district court decision requiring the U.S. Patent and Trademark Office (PTO) to consider an application...
07:00 , Apr 19, 2010 |  BC Week In Review  |  Company News

Debiopharm, Sun Pharmaceutical, Actavis, Hospira, Par Pharmaceutical, sanofi-aventis cancer news

Debiopharm and sanofi-aventis settled additional patent suits related to cancer chemotherapeutic Eloxatin oxaliplatin, which the pharma markets in the U.S. under license from Debiopharm. Under the settlement, Actavis, Hospira and Par would stop selling generics...